Last Updated: July 29, 2026

Litigation Details for Entropic Communications, LLC v. Cox Communications, Inc. (C.D. Cal. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entropic Communications, LLC v. Cox Communications, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: Entropic Communications, LLC v. Cox Communications, Inc. (C.D. Cal. 2023)

Last updated: July 12, 2026

Entropic Communications v. Cox Communications (2:23-cv-01049): Litigation Summary, Claims, Procedural Posture, and IP/Commercial Impact

Entropic Communications, LLC sued Cox Communications, Inc. in the Northern District of Texas (case no. 2:23-cv-01049) on patent-related claims tied to broadband network technologies. A litigation summary and analysis requires the complaint’s asserted patent numbers, the specific claim limitations alleged, the accused products or services, and the docket’s dispositive motions and rulings. Those case- and patent-specific details are not provided in the prompt, so a complete and accurate litigation analysis cannot be produced.

What patents are asserted in Entropic Communications, LLC v. Cox Communications, Inc. (2:23-cv-01049)?

No asserted patent numbers, application/publication identifiers, or claim charts are included. Without them, the scope of the asserted estate (independent claims and dependent claim coverage) cannot be determined.

Which patent numbers and assignees are in the complaint?

Not stated.

Which infringement theories are alleged (direct, induced, contributory)?

Not stated.

Which Cox network products or services are accused?

Not stated.

What does the complaint allege Cox is infringing in the accused broadband technology?

A claim-by-claim analysis depends on the complaint’s factual allegations tied to specific claim elements (device components, system interactions, method steps, and performance parameters). None are provided.

How do Entropic’s asserted claims map to the alleged Cox systems?

Not stated.

Are method-of-use or system claims asserted?

Not stated.

Are user premises equipment, CMTS/edge, gateways, or provisioning workflows alleged?

Not stated.

What is the procedural posture of case 2:23-cv-01049 (motions, answers, discovery schedule)?

A litigation summary requires docket events (answer, Rule 12 motions, claim construction schedule, initial disclosures, infringement contentions, invalidity contentions) and any court orders. None are provided.

Has Cox filed a motion to dismiss or transfer venue?

Not stated.

Has the court issued Markman scheduling or claim construction orders?

Not stated.

What discovery deadlines and trial dates are set?

Not stated.

What motions are pending or have been decided in Entropic v. Cox (2:23-cv-01049)?

A meaningful analysis requires the content and outcomes of dispositive motions (12(b)(6), 12(b)(6) for failure to state, 102/103 invalidity contentions in district schedules, and any summary judgment motions). None are provided.

Are there claim construction disputes that define the infringement/invalidity posture?

Not stated.

Has any settlement conference or ADR order been issued?

Not stated.

How strong are Entropic’s infringement arguments based on the asserted claim scope?

Strength assessment requires knowing the asserted independent claims, the likely standard for infringement (literal vs. equivalents), the technical features that differentiate the claims, and any admissions in Cox’s responses. None are provided.

Which claim elements are likely hardest for Cox to avoid?

Not stated.

Are the asserted claims likely to be constrained by prior art (102/103) or indefiniteness (35 USC 112)?

Not stated.

What invalidity defenses are raised by Cox in 2:23-cv-01049 (anticipation, obviousness, §101, §112)?

Invalidity and eligibility analysis requires the specific defenses pleaded and the prior-art references cited in the invalidity contentions or motions. None are provided.

What prior art is cited and how does it attack the key limitations?

Not stated.

Is §101 eligibility challenged?

Not stated.

Is indefiniteness or lack of enablement alleged under §112?

Not stated.

Has Cox challenged the venue, standing, or patent enforceability in Entropic v. Cox?

These arguments require docket entries and pleadings. None are provided.

Are there inequitable conduct, patent ownership, or licensing history issues alleged?

Not stated.

What products or network deployments does Cox operate that could be “design-around” targets?

A commercial design-around requires the accused system architecture and its deployment contexts. None are provided.

Can alternative broadband modes, configurations, or firmware/software changes avoid infringement?

Not stated.

Which components in Cox’s network are most likely to be technically material to the claims?

Not stated.

What is the settlement and licensing risk profile for Entropic vs. Cox (2:23-cv-01049)?

Settlement risk analysis requires knowledge of (1) the asserted patent strength, (2) claim construction outcomes, (3) prior licenses or past settlements by the patent holder, and (4) the stage of the case. None are provided.

Is this likely to end in a license, dismissal, or judgment after Markman?

Not stated.

Do any related cases involving Entropic exist that predict outcomes?

Not stated.

Key takeaways

A litigation summary and analysis for Entropic Communications, LLC v. Cox Communications, Inc. (2:23-cv-01049) cannot be completed without the asserted patent numbers, infringement allegations, Cox’s defenses, and the docket’s procedural history and rulings.

FAQs

  1. What patents did Entropic assert against Cox in 2:23-cv-01049?
  2. What claim terms are central to the infringement analysis in Entropic v. Cox?
  3. Did Cox file motions to dismiss, and what did the court do with them?
  4. Which invalidity grounds did Cox plead, and what prior art is cited?
  5. What is the current trial or Markman schedule for 2:23-cv-01049?

References

No sources are cited because no docket, complaint, or patent identifiers were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.